Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
Anavex reported preliminary Q2 cash of $127.4 million, up from $102.6 million in September, with a narrowed net loss of $5.3 million compared to $11.2 million a year prior. The company expects this cash balance to fund operations into mid-to-late fiscal 2028, citing decreased R&D expenses following the completion of its schizophrenia trial.
Key figures
- Net loss
- 5300000
- Cash runway
- mid-to-late fiscal 2028
- Ga expenses
- 2300000
- Rd expenses
- 4200000
- Cash balance
- 127400000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.